UBC Faculty Research and Publications

The Impact of the Meningococcal Serogroup C Conjugate Vaccine in Canada Between 2002 and 2012 Sadarangani, Manish; Scheifele, David W.; Halperin, Scott A.; Vaudry, Wendy; Le Saux, Nicole; Tsang, Raymond; Bettinger, Julie A.

Abstract

Background. Before 2001, the incidence of invasive meningococcal disease (IMD) in Canada was 1.0 per 100 000 per year, with 40% of cases caused by serogroup C organisms. During 2001–2005 all provinces introduced the meningococcal serogroup C conjugate vaccine (MCCV) into their routine infant immunization schedule. Methods. Active, prospective, population-based surveillance of IMD in children and adults was conducted by the Canadian Immunization Monitoring Program, ACTive (IMPACT) during 2002–2012. Inclusion criteria were admission to hospital and identification of Neisseria meningitidis from a sterile site. Incidence was estimated using population census data from Statistics Canada. Results. Prior to MCCV introduction, serogroup C disease incidence was 0.07–0.25 per 100 000 per year depending on the province. Following vaccine introduction, serogroup C disease decreased to

Item Citations and Data

Rights

Attribution-NonCommercial-NoDerivs 2.5 Canada

Usage Statistics